Nicola Deidre Petal Greenway Sells 6,774 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 6,774 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $115,835.40. Following the sale, the insider directly owned 53,029 shares of the company’s stock, valued at approximately $906,795.90. This represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $17.41 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The stock has a market capitalization of $55.77 billion, a P/E ratio of 51.19 and a beta of -0.08. The company’s fifty day moving average is $16.53 and its two-hundred day moving average is $17.14. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, sell-side analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors have recently made changes to their positions in TAK. Royal Bank of Canada lifted its stake in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares during the period. AQR Capital Management LLC grew its position in Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after buying an additional 59,442 shares during the period. Goldman Sachs Group Inc. grew its position in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares during the period. Focus Partners Wealth increased its holdings in Takeda Pharmaceutical by 4.1% in the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in Takeda Pharmaceutical in the second quarter valued at about $351,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Wall Street Analysts Forecast Growth

TAK has been the subject of a number of recent analyst reports. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical currently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.